See more : Guidewire Software, Inc. (GWRE) Income Statement Analysis – Financial Results
Complete financial analysis of Enanta Pharmaceuticals, Inc. (ENTA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Enanta Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Total Telcom Inc. (TTZ.V) Income Statement Analysis – Financial Results
- Hong Yuan Holding Group (HGYN) Income Statement Analysis – Financial Results
- Valiant Communications Limited (VALIANT.BO) Income Statement Analysis – Financial Results
- Zevotek, Inc. (ZVTK) Income Statement Analysis – Financial Results
- NovX21 Inc. (PORMF) Income Statement Analysis – Financial Results
Enanta Pharmaceuticals, Inc. (ENTA)
About Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 67.64M | 79.20M | 86.16M | 97.07M | 122.47M | 205.20M | 206.63M | 102.81M | 88.27M | 160.88M | 47.74M | 32.05M | 41.71M | 41.88M | 22.76M |
| Cost of Revenue | 0.00 | 0.00 | 2.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 67.64M | 79.20M | 83.19M | 97.07M | 122.47M | 205.20M | 206.63M | 102.81M | 88.27M | 160.88M | 47.74M | 32.05M | 41.71M | 41.88M | 22.76M |
| Gross Profit Ratio | 100.00% | 100.00% | 96.55% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 131.48M | 163.52M | 164.52M | 174.11M | 136.76M | 142.21M | 94.86M | 57.45M | 40.46M | 23.19M | 18.74M | 16.84M | 15.12M | 11.55M | 9.72M |
| General & Administrative | 57.85M | 52.89M | 45.48M | 32.54M | 27.36M | 26.25M | 23.44M | 20.75M | 16.97M | 13.54M | 10.02M | 6.18M | 5.30M | 0.00 | 6.11M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 57.85M | 52.89M | 45.48M | 32.54M | 27.36M | 26.25M | 23.44M | 20.75M | 16.97M | 13.54M | 10.02M | 6.18M | 5.30M | 5.04M | 6.11M |
| Other Expenses | 0.00 | 0.00 | 83.00K | 1.99M | 6.62M | 8.82M | 4.79M | 2.33M | 1.72M | 1.31M | 283.00K | 598.00K | 0.00 | 5.04M | 309.00K |
| Operating Expenses | 189.33M | 216.41M | 210.00M | 206.65M | 164.11M | 168.46M | 118.30M | 78.20M | 57.43M | 36.73M | 28.76M | 23.02M | 20.42M | 16.58M | 15.82M |
| Cost & Expenses | 189.33M | 216.41M | 210.00M | 206.65M | 164.11M | 168.46M | 118.30M | 78.20M | 57.43M | 36.73M | 28.76M | 23.02M | 20.42M | 16.58M | 15.82M |
| Interest Income | 14.77M | 11.36M | 1.57M | 2.02M | 6.47M | 8.82M | 0.00 | 2.53M | 1.74M | 968.00K | 467.00K | 248.00K | 118.00K | 83.00K | 14.00K |
| Interest Expense | 10.94M | 5.15M | 1.57M | 0.00 | 0.00 | 8.82M | 4.85M | 40.00K | 45.00K | 8.00K | 18.00K | 31.00K | 0.00 | 3.16M | 0.00 |
| Depreciation & Amortization | 2.34M | 2.37M | 2.97M | 3.33M | 3.64M | 3.26M | 2.52M | 2.14M | 1.66M | 639.00K | 352.00K | 221.00K | 172.00K | 499.00K | 553.00K |
| EBITDA | -104.51M | -123.48M | -119.22M | -104.25M | -38.00M | 40.00M | 90.85M | 26.75M | 32.50M | 124.79M | 19.34M | 9.25M | 21.57M | 26.97M | 8.30M |
| EBITDA Ratio | -154.52% | -155.90% | -140.38% | -112.88% | -34.00% | 17.90% | 42.75% | 23.94% | 34.94% | 77.17% | 39.77% | 28.17% | 51.74% | 61.80% | 34.35% |
| Operating Income | -121.69M | -137.21M | -123.84M | -109.57M | -41.64M | 36.74M | 88.33M | 24.61M | 30.84M | 124.15M | 18.99M | 9.03M | 21.29M | 25.30M | 6.94M |
| Operating Income Ratio | -179.92% | -173.23% | -143.74% | -112.88% | -34.00% | 17.90% | 42.75% | 23.94% | 34.94% | 77.17% | 39.77% | 28.17% | 51.05% | 60.41% | 30.50% |
| Total Other Income/Expenses | 3.90M | 6.21M | 1.66M | 1.99M | 6.62M | 8.82M | 4.79M | 2.33M | 1.72M | 1.31M | 283.00K | 598.00K | 110.00K | -1.99M | 805.00K |
| Income Before Tax | -117.79M | -131.00M | -122.19M | -107.58M | -35.02M | 45.56M | 93.12M | 26.95M | 32.56M | 125.46M | 19.27M | 9.63M | 21.40M | 23.31M | 7.75M |
| Income Before Tax Ratio | -174.15% | -165.39% | -141.82% | -110.82% | -28.59% | 22.20% | 45.07% | 26.21% | 36.89% | 77.98% | 40.36% | 30.03% | 51.31% | 55.66% | 34.03% |
| Income Tax Expense | -1.74M | 2.82M | -433.00K | -28.58M | 1.15M | -826.00K | 21.17M | 9.24M | 10.89M | 46.46M | -15.17M | -221.00K | 0.00 | 3.16M | -157.00K |
| Net Income | -116.05M | -133.82M | -121.76M | -79.00M | -36.17M | 46.38M | 71.96M | 17.71M | 21.67M | 78.99M | 34.44M | 9.63M | 21.40M | 23.31M | 7.90M |
| Net Income Ratio | -171.58% | -168.95% | -141.31% | -81.38% | -29.53% | 22.60% | 34.82% | 17.23% | 24.55% | 49.10% | 72.14% | 30.03% | 51.31% | 55.66% | 34.72% |
| EPS | -5.48 | -6.38 | -5.91 | -3.92 | -1.81 | 2.37 | 3.48 | 0.93 | 1.14 | 4.23 | 1.88 | -0.67 | 1.18 | 1.35 | 0.02 |
| EPS Diluted | -5.48 | -6.38 | -5.91 | -3.92 | -1.81 | 2.21 | 3.48 | 0.91 | 1.13 | 4.09 | 1.80 | -0.67 | 0.52 | 0.59 | 0.02 |
| Weighted Avg Shares Out | 21.16M | 20.97M | 20.60M | 20.17M | 19.94M | 19.58M | 20.65M | 19.07M | 18.93M | 18.67M | 18.36M | 9.79M | 1.16M | 1.16M | 12.75M |
| Weighted Avg Shares Out (Dil) | 21.16M | 20.97M | 20.60M | 20.17M | 19.94M | 20.97M | 20.65M | 19.41M | 19.22M | 19.30M | 19.19M | 9.79M | 2.64M | 2.64M | 14.13M |
Enanta Pharmaceuticals Initiates a Phase 2b Clinical Study of EDP-938 in High-Risk Adults with Respiratory Syncytial Virus
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the initiation of a Phase 2b, randomized, double-blind, placebo-controlled study to evaluate the efficacy and...
Enanta Pharmaceuticals Presents Preclinical Data for its Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) Programs at the 12th International RSV Symposium
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced new preclinical data related to its RSV program, as well as new virology methods used...
Enanta Pharmaceuticals Announces New Preclinical Data for its Respiratory Virology Programs to be Presented at the 12th International RSV Symposium
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that new preclinical data related to its respiratory syncytial virus (RSV) program, as well as...
New Preclinical Data for EDP-235, Enanta's Oral Coronavirus Protease Inhibitor Designed for the Treatment of COVID-19, to be Presented at IDWeek™ 2022
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that new preclinical data for EDP-235, its lead oral coronavirus protease inhibitor specifically designed for...
Enanta Pharmaceuticals to Participate in Two Investor Conferences in September
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two investor...
Enanta Pharmaceuticals, Inc. (ENTA) CEO Jay Luly on Q3 2022 Results - Earnings Call Transcript
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA ) Q3 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Jennifer Viera - Senior Director, IR & Corporate Communications Jay Luly - President, CEO & Director Paul Mellett - SVP, Finance &...
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -12.50% and 3.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Enanta Pharmaceuticals Appoints Scott T. Rottinghaus, M.D.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and liver diseases, today announced the appointment of Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical...
Enanta Pharmaceuticals to Host Conference Call on August 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2022
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal third quarter ended June...
Source: https://incomestatements.info
Category: Stock Reports